As a result of this treatment regimen, within 10–20 weeks of promotion, mice develop premalignant squamous tumors papillomas harboring activating mutations in the Hras oncogene, followed by a progression of a portion of papillomas to cSCC within 20–50 weeks (214, 215). Here, HRAS is linked to skin squamous cell carcinoma.